Close

UPDATE: Roth Capital Upgrades ImmunoCellular Therapeutics (IMUC) to Buy

June 2, 2014 8:26 AM EDT Send to a Friend
(Updated - June 2, 2014 9:23 AM EDT)

Roth Capital upgraded ImmunoCellular Therapeutics (NYSE: IMUC) from Neutral to Buy ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login